Tumor necrosis factor-alpha and neuropsychiatric lupus erythematosus: Relation to single photon emission computed tomography findings

Modern Rheumatology

Volumn 13, Issue 3, 2003, Pages 250-255

  El Zorkany, Bassel ^a   Mahmoud, Geilan A ^a   Shahin, Hesham A ^a   Moustafa, Hosna ^a   Shahin, Amira A ^a  

^a CAIRO UNIVERSITY   (Egypt)

Author keywords

Neuropsychiatric lupus erythematosus (NPLE); Neuropsychiatry; Single photon emission computed tomography (SPECT); Systemic lupus erythematosus (SLE); Tumor necrosis factor (TNF )

Indexed keywords

ANTIMALARIAL AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; STEROID; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADOLESCENT; ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL FEATURE; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DISEASE ACTIVITY; ENZYME IMMUNOASSAY; EVALUATION; FEMALE; HUMAN; HYPOTHESIS; IMAGE ANALYSIS; LABORATORY TEST; PATHOGENESIS; PERFUSION; PRIORITY JOURNAL; PSYCHOPATHY; SENSITIVITY ANALYSIS; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY; STATISTICAL ANALYSIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 0141892679     PISSN: 14397595     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10165-003-0231-z     Document Type: Article

References (38)

1. Boumpass DT, Scott D, Balow JE. Neuropsychiatric lupus: a case for guarded optimism [Editorial]. J Rheumatol 1993;20:1641-3.
2. Bonfa E, Golombek S, Kaufman LD, Skelly S, Weissbach H, Brot N, et al. Association between lupus psychosis and anti-ribosomal P protein antibodies. N Engl J Med 1987;317:265-71.
3. Denburg S, Behmnann S, Carbotte R, Denbur J. Lymphocyte antigens in neuropsychiatric systemic lupus erythematosus. Arthritis Rheum 1994;37:369-75.
4. Toubi E, Khamashta M, Panarra A, Hughes G. Association of antiphospholipid antibodies with central nervous system disease in systemic lupus erythematosus. Am J Med 1995;99:397-401.
5. Arditi M, Manogue KR, Kaplan M, Yogev R. Cerebrospinal fluid cachectin/tumor necrosis factor-alpha and platelet-activating factor concentrations and severity of bacterial meningitis. J Infect Dis 1990;62:139-47.
6. Hirohata S, Miyamoto T. Elevated levels of interleukin-6 in cerebrospinal fluid from patients with systemic lupus erythematosus and central nervous system involvement. Arthritis Rheum 1990;33: 644-9.
7. Alcocer-Varela J, Aleman-Hoey D, Alarcon-Segovia D. Interleukin-1 and interleukin-6 are increased in the cerebrospinal fluid of patients with CNS lupus erythematosus and correlate with local late T-cell activity markers. Lupus 1992;1:111-7.
8. Shiozawa S, Kuroki Y, Kim M, Hirohata S, Ogino T. Interferon-alpha in lupus psychosis. Arthritis Rheum 1992;35:417-22.
9. Blakwill FR. Tumour necrosis factor. Br Med Bull 1989;45:389-400.
10. Jacob CO, Fronek Z, Lewis GD, Koo M, Hansen JA, McDevitt HO. Heritable MHC Class II associated difference in production of TNF-α: relevance to genetic predisposition to SLE. Proc Natl Acad Sci USA 1990;87:1233-7.
11. Rood MJ, Van Krugten MV, Zanelli E, Van der Lindin MW, Keijsers V, Schreuder GMT, et al. TNF-308A and HLA-DR3 alleles contribute independently to susceptibility to systemic lupus erythematosus. Arthritis Rheum 2000;43:129-34.
12. Kovacs JAJ, Murray B, Urowitz Z, Dafina D, Goldman A, Zemen R. The use of SPECT in neuropsychiatric SLE: a pilot study. J Rheumatol 1995;22:1247-53.
13. Rubbert A, Marienj HJ, Pirner K, Manger B, Grebmeirr J, Engelhardt A, et al. Single photon emission computed tomography analysis of cerebral blood flow in the evaluation of central nervous system involvement in patients with systemic lupus erythematosus. Arthritis Rheum 1993;36:1251-62.
14. Tan EM, Cohen AS, Fries JF, Masi AT, McShane DJ, Rothfield NF, et al. The 1982 revised criteria for the classification of SLE. Arthritis Rheum 1982;25:1271-7.
15. Ainiala H, Hietaharju A, Loukkola J, Peltola J, Korpela M, Metsanoja R, et al. Validity of the new American College of Rheumatology criteria for the neuropsychiatric lupus syndrome: a population-based evaluation. Arthritis Rheum 2001;45:419-23.
16. Bombardier C, Gladman DD, Urowitz M. Derivation of the SLEDAI. A disease activity index for lupus patients. Arthritis Rheum 1992;29:981-5.
17. Jacob CO, McDevitte HO. Tumor necrosis factor-alpha in murine autoimmune lupus nephritis. Nature 1988;331:356-8.
18. Brennan DC, Yui MA, Wuthrich RP, Kelley VE. Tumor necrosis factor and IL-1 in New Zealand black/white mice: enhanced gene expression and acceleration of renal injury. J Immunol 1989;143: 3470-5.
19. Jacob CO, Lewis GD, McDevitte HO. MHC class II-associated variations in the production of tumor necrosis factor in mice and humans: relevance to the pathogenesis of autommume disease. Immunol Res 1991;10:156-68.
20. Selmaj K, Reine CS, Cross AH. Anti-tumor necrosis factor therapy abrogates autoimmune demyelination. Ann Neurol 1991;30:694-700.
21. Hoffman FM, Hinton DR, Johnson K, Merrile JE. Tumor necrosis factor identified in multiple sclerosis brain. J Exp Med 1989;170: 607-12.
22. Sharieff MK, Hentages R. Association between tumor necrosis factor-alpha and disease progression in patients with multiple sclerosis. N Engl J Med 1091;523:467-72.
23. Mohan N, Edwards ET, Cupps TR, Oliverio PJ, Sandburg G, Crayton H, et al. Demyelination occurring during anti-tumor necrosis factor therapy for inflammatory arthritides. Arthritis Rheum 2001;44:2862-9.
24. Liu J, Marino MW, Wong G, Grail D, Dunn A, Bettadapura J, et al. TNF is a potent tumor necrosis factor cytokine in auto-immune-mediated demyelination. Nat Med 1998;4:78-83.
25. Murry CP, Teppo AM. Tumor necrosis factor in the serum of patients with systemic lupus erythematosus. Arthritis Rheum 1989; 32:146-50.
26. Aderka D, Wysenbeek A, Engelmann H. Correlation between serum levels of soluble TNF-R and disease activity in SLE. Arthritis Rheum 1993;36:1111-20.
27. Meijer C, Huysen V, Smeenk RTJ, Swaak AJG. Profiles of cytokines (TNF-α and IL-6) and acute-phase proteins (CRP and α-IAG) related to the disease course in patients with SLE. Lupus 1993;2:359-65.
28. Studnicka-Benke A, Steiner G, Petera P, Smolen JS. Tumor necrosis factor-alpha and its soluble receptors parallel clinical disease and autoimmune activity in systemic lupus erythematosus. Br J Rheum 1996;35:1067-74.
29. Miret C, Font J, Molina R, Garcia-Carrasco M, Filella X, Ramos M, et al. Relationship of oncogenes (sFas, Bcl-2) and cytokines (IL-10, alfa-TNF) with the activity of systemic lupus erythematosus. Anticancer Res 2001;21:3053-9.
30. Alvarado-de la Barrera C, Alcocer Varela J, Richard-Patin Y, Alarcon-Segovia D, Llorente L. Differential oncogene and TNF-alpha mRNA expression in bone marrow cells from systemic lupus erythematosus patients. Scand J Immunol 1998;48:551-6.
31. Gattoron M, Picco P, Barbano G, Stalla F, Sormani MP, Buoncompagni A, et al. Differences in tumor necrosis factor-alpha soluble receptor serum concentration between patients with Henoch-Schonlein purpura and pediatric systemic lupus erythematosus. J Rheumatol 1998;25:361-5.
32. Robak E, Sysa-Jedrzejewska A, Dziankowska B, Torzecka D, Chojnowski K, Robak T. Association of interferon-gamma, tumor necrosis factor-alpha and interleukin-6 serum levels with systemic lupus erythematosus activity. Arch Immunol Ther Exp 1998;46: 376-80.
33. Korner H, Riminton DS, Strickland DH, Lemckert FA, Pollard JD. Sedgwick JD. Critical points of tumor necrosis factor action in central nervous system autoimmune inflammation defined by gene targeting. J Exp Med 1997;189:1585-90.
34. Svenungsson E, Andersson M, Brundin L, Van Vollenhoven R, Khademi M, Tarkowski A, et al. Increased levels of proinflammatory cytokines and nitric oxide metabolites in neuropsychiatric lupus erythematosus. Ann Rheum Dis 2001;60:372-9.
35. Smolen J. Therapy of systemic lupus erythematosus: a look into the future. Arthritis Res 2002;4 Suppl 3:S25-30.
36. Falcini F, De Cristofaro MTR, Ermini M, Guarnieri M, Massi G, Olmastroni M, et al. Regional cerebral blood flow in juvenile systemic lupus erythematosus: a prospective SPECT study. J Rheumatol 1998;25:583-8.
37. Russo R, Gilday D. Laxer RM, Eddy A, Silverman ED. Single photon emission computed tomography scanning in childhood systemic lupus erythematosus. J Rheumatol 1998;25:576-82.
38. Segal R, Dayan M, Zinger H, Mozes E. Suppression of experimental systemic lupus erythematosus in mice via TNF inhibition by an anti-TNF-alpha monoclonal antibody and by pentoxiphylline. Lupus 2001;10:23-31.